Bone morphogenetic protein in spine surgery: current and future uses

J Am Acad Orthop Surg. 2012 Sep;20(9):547-52. doi: 10.5435/JAAOS-20-09-547.

Abstract

The clinical use of bone morphogenetic protein (BMP) in spinal fusion surgery has recently become controversial. After its approval by the US FDA in July 2002, BMP was adopted by many spine surgeons as a replacement for the more traditional iliac crest bone graft to avoid the complications associated with bone graft harvest. However, as broad clinical use escalated, reports increased of potentially serious complications associated with BMP. Controversy continues, particularly regarding the safety of BMP and whether it should routinely replace iliac crest bone graft for spinal fusion surgery.

Publication types

  • Review

MeSH terms

  • Bone Morphogenetic Protein 2 / therapeutic use
  • Bone Morphogenetic Proteins / therapeutic use*
  • Bone Substitutes*
  • Humans
  • Ilium / transplantation
  • Recombinant Proteins / therapeutic use
  • Spinal Fusion* / trends
  • Transforming Growth Factor beta / therapeutic use

Substances

  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins
  • Bone Substitutes
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2